Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.730
+0.010 (0.58%)
At close: Feb 21, 2025, 4:00 PM
1.700
-0.030 (-1.73%)
After-hours: Feb 21, 2025, 7:59 PM EST
Heron Therapeutics Revenue
Heron Therapeutics had revenue of $32.81M in the quarter ending September 30, 2024, with 4.38% growth. This brings the company's revenue in the last twelve months to $137.74M, up 12.13% year-over-year. In the year 2023, Heron Therapeutics had annual revenue of $127.04M with 17.99% growth.
Revenue (ttm)
$137.74M
Revenue Growth
+12.13%
P/S Ratio
1.91
Revenue / Employee
$1,093,151
Employees
126
Market Cap
263.12M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 127.04M | 19.37M | 17.99% |
Dec 31, 2022 | 107.67M | 21.33M | 24.70% |
Dec 31, 2021 | 86.35M | -2.29M | -2.59% |
Dec 31, 2020 | 88.64M | -57.33M | -39.28% |
Dec 31, 2019 | 145.97M | 68.49M | 88.41% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
HRTX News
- 8 days ago - Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 - PRNewsWire
- 2 months ago - Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina - PRNewsWire
- 2 months ago - Relief For Heron Therapeutics After The Court Win On Cinvanti - Seeking Alpha
- 2 months ago - U.S. District Court Upholds Validity of CINVANTI® Patents - PRNewsWire
- 3 months ago - Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance - PRNewsWire
- 3 months ago - Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - PRNewsWire
- 4 months ago - Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 - PRNewsWire